Protocol EC-FV-01: A phase I study of EC145 administered in weeks 1 and 3 of a 4-week cycle
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Vintafolide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Endocyte
- 30 Sep 2008 Checked against clinicaltrials.gov record, added actual patient number.
- 28 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
- 19 Jul 2007 Status changed from recruiting to in progress.